Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Seretide evidence
Seretide efficacy and clinical evidence
Read the information below to understand the key clinical evidence for Seretide in asthma and COPD.
Asthma summary
Asthma patients uncontrolled on ≤ 500mcgs BDP or equivalent when stepped up to Seretide can
experience [1],[2]
- 88% of rescue medication free days over one year*
- 74% of symptom free days over one year*
- 75% patients achieved guideline-defined control after one year
* This was demonstrated in a post-hoc analysis of the GOAL study.[1],[2]
Read the GOAL study summary below or the GOAL study in full
COPD summary
Short-term benefits
COPD patients on Seretide 500 Diskus experienced an improvement in:
- lung function after 24 hours measured as PEFR vs. placebo, salmeterol and fluticasone propionate in a patient subgroup with baseline FEV1 <50% predicted (p<0.0001)[3]
- breathlessness after 48 hours compared with placebo in a patient subgroup with baseline FEV1 <50% predicted (p<0.001)[3]
Long-term benefits
TORCH was a 3 year study. The primary endpoint of the effect of Seretide 500 Diskus on all-cause mortality did not meet statistical significance; P=0.052 [4]
Additionally, over 3 years, COPD patients taking Seretide 500 Diskus experienced:
- a 43% reduction in the rate of exacerbations requiring oral steroids compared with placebo (p<0.001) ARR = – 0.34 exacerbations/yr (0.46 Seretide 500 Diskus vs. 0.80 placebo) [4]
- Improvement in quality of life measured with SGRQ [4]
- Reduced rate of lung function decline by 16mL per year compared with placebo (in a post-hoc analysis) (p<0.001) [5]
Read the TORCH study summary below or the TORCH study in full
Evidence for Seretide in adults with asthma:
Gaining Optimal Asthma control The "GOAL" study summary [1],[2]
Evidence for Seretide 50/25 Evohaler or 100/50 Diskus in children with asthma:
De Blic et al. study summary [6]
For further information on how Seretide offers an effective asthma treatment for children aged four years and older, see our Paediatrics page.
Evidence for Seretide 500/50 Diskus in adults with COPD
TORCH (TOwards a Revolution in COPD Health) study summary[4]
INSPIRE study summary[7]
Kardos et al. study summary[8]
References:
- Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med. 2004; 170:836-844
- Woodcock AA et al; Prim Care Respir J. 2007; 16(3): 155-161
- Vestbo et al; ATS Poster 2003
- Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2007; 356:775-789
- Celli et al; Am J Respir Crit Care Med; 2008; 178; 332-338
- De Blic J et al. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. Pediatr Allergy Immunol 2009
- Wedzicha JA et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177:19–26
- Kardos P et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:144–149
Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Seretide, Diskus and Evohaler are registered trademarks of the GlaxoSmithKline Group of Companies
